Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Bepreve on Histamine Skin Prick Test Response
NCT01128556Phase 4
Key facts
- Status
- Completed
- Start
- Apr 2010
- Primary completion
- Jun 2010
- Countries
- 1
- Sponsor
- North Texas Institute for Clinical Trials
- Modality
- Small Molecules
- Drugs
- bepotastine
- Conditions
- allergic conjunctivitis (AC)
01
Overview
Phase 4, open-label, single-arm trial of bepotastine in allergic conjunctivitis (AC), sponsored by North Texas Institute for Clinical Trials. Primary endpoint: measurement of Wheal and Flare response from histamine skin-prick testing at 7 days. Started Apr 2010; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Bepreve Sequence
Bepreve followed by Refresh Tears
03
Who it enrols
Healthy subjects aged 18-65 with a positive histamine skin-prick test (wheal >3mm) are eligible. Patients with active allergic disease symptoms, recent respiratory infections, asthma, dermatographism, or those receiving immunotherapy are excluded.
04
Endpoints
Primary
measurement of Wheal and Flare response from histamine skin-prick testing
Beyond the preview
Go deeper on NCT01128556.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01128556.